Design Space Development for Lyophilization Using DOE and Process Modeling - Develop a relevant design space without full factorial DoE. - BioPharm International


Design Space Development for Lyophilization Using DOE and Process Modeling
Develop a relevant design space without full factorial DoE.

BioPharm International
Volume 23, Issue 9


In the Quality by Design framework, there is a significant emphasis on the robust characterization of manufacturing processes and prospectively identifying manufacturing design space that ensures product quality. In this article, we discuss an approach that leverages risk assessments, design of experiments, and mechanistic modeling of unit operations to establish a design space that is relevant for manufacturing. We present an overview of our methodology and its application to lyophilization process characterization for a monoclonal antibody formulation.

Genentech, Inc.
Lyophilization is a drying process in which a formulation containing the active pharmaceutical ingredient of interest is frozen at low temperatures (well below 0 C) and water is then sublimed by subjecting it to low pressure. Removal of water in this manner preserves the physical and biochemical attributes of the product, thus resulting in good long-term stability. In a typical lyophilization process, the drying consists of a primary drying step, in which low pressure provides the driving force for frozen water in the product to start subliming; and a secondary drying step to remove any residual adsorbed water by desorption. Figure 1 shows a schematic of a lyophilizer with three main components—the drying chamber in which vials are heated or cooled; the vacuum pump, which provides low pressure in the chamber; and a condenser, which traps water vapor leaving the vials.

Figure 1. Schematic of a lyophilization unit operation
The Quality by Design (QbD) philosophy is increasingly being adopted in the pharmaceutical and biopharmaceutical industries.1,2 From a manufacturing perspective, this translates into leveraging a sound, scientific understanding of unit operations to design a manufacturing process with prospectively defined multivariate parameter ranges that produce acceptable product quality attributes. In the QbD framework, the multidimensional combination and interaction of input variables that have been demonstrated to provide assurance of quality is termed the design space. Approaches for identifying the design space in the pharmaceutical industry that are discussed in the scientific literature or at conferences generally rely on statistical design of experiments (DOE), which can be resource intensive.3–5 In cases where the number of input variables is large, performing a full-blown statistical DOE may simply be impractical.

Figure 2. Methodology for developing a design and excursion space for lyophilization. Details of the use of the model to expand the design space are shown in Figure 7.
In this article, we present a methodology in which a combination of a statistical DOE and a mechanistic mathematical model was used to arrive at larger and practically relevant design space with fewer experiments than a full factorial DOE. Figure 2 presents a flowchart illustrating our approach to developing a design space for lyophilization.

Figure 3. Freeze-drying microscopy of a model antibody formulation
In the subsequent sections, we will further illustrate some of the steps in this methodology using a case study for lyophilization of a monoclonal antibody (MAb).

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here